POLB 001 LPS human challenge trial completed

Poolbeg Pharma

12/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221212:nRSL2894Ja&default-theme=true

RNS Number : 2894J  Poolbeg Pharma PLC  12 December 2022

 

Poolbeg Pharma plc

 

POLB 001 LPS human challenge clinical trial successfully completed

No serious adverse events reported

Results of full data analysis expected in Q2 2023

 

12 December 2022 - Poolbeg Pharma (http://www.poolbegpharma.com/) (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading infectious disease
focused biopharmaceutical company, announces that, further to its announcement
in July 2022
(https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/xl85g9w)
, it has now received the initial results having completed the
Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral
strain agnostic, small molecule immunomodulator being developed to address the
unmet medical need for severe influenza.

 

Key highlights from the study:

 

·     No further clinical activity is required to complete the
objectives of the trial, bringing the recruitment and clinical phase to a
close on schedule

·    No serious adverse events reported. POLB 001 was found to be safe and
well tolerated

·     Data analysis has commenced and full data read-out is expected in
Q2 2023

·    The comprehensive dataset is expected to facilitate progression of
the product to the next clinical phase for potential partners

 

This LPS challenge trial was designed to evaluate the effect of POLB 001 on
inflammatory responses in 36 healthy volunteers between 18 and 55 years of age
following an intradermal and an intravenous LPS challenge. LPS acts as a
surrogate for the hyperinflammatory response associated with severe influenza
and other diseases.

 

POLB 001 is a unique potential treatment for viruses such as severe influenza
as it is strain agnostic, unlike other flu treatments and prophylactics. This
means that it can be effective regardless of which strain of influenza is
dominant in any particular season or geography. As a shelf-stable, oral drug
it could also be ideal as a stockpiling candidate for both seasonal outbreaks
and pandemic preparedness.

 

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

 

"We have completed our first trial on schedule, achieving a key milestone for
Poolbeg, thanks to the committed efforts of the team. We are actively planning
the next steps for POLB 001 and are engaging with industry on potential
partnering opportunities.

 

"The threat of influenza shouldn't be underestimated. Cases are on the rise -
the WHO estimates that there are 3-5 million severe influenza cases globally
per year, with real pandemic potential. Severe influenza can also lead to
other major complications such as pneumonia and stroke. There is a significant
unmet need for severe influenza treatments, so we eagerly anticipate the full
results of this study next year."

 

Matthijs Moerland, PhD, Principal Investigator at CHDR, said:

 

"LPS human challenge trials are a highly reliable way of measuring the
efficacy of anti-inflammatory drugs and these initial data are an important
first step.  We are pleased to be involved in the development of a potential
treatment for such an unmet need as severe influenza and we look forward to
the vital insights that the full analysis will bring."

 

-Ends-

Enquiries

 Poolbeg Pharma Plc                                            +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 finnCap Ltd (Nominated Adviser & Joint Broker)                +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                          +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                       +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                              +44 (0) 208 078 4357

 Mary Clark, Nick Bastin, Manel Mateus, Vici Rabbetts          poolbeg@optimumcomms.com

 

About Poolbeg Pharma

 

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in prevalent and emerging infectious diseases. Poolbeg
has a disciplined portfolio approach to mitigate risk, accelerate drug
development and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, and in-license near or in the clinic
medicines, leading to faster development and greater commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025.

 

With its initial assets from  (http://www.hvivo.com) hVIVO plc (formerly Open
Orphan plc), an industry leading infectious disease and human challenge trials
business, Poolbeg has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these insights
to acquire new assets as well as reposition clinical stage products, reducing
spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza (POLB 001) which has completed
its LPS human challenge trial with full data read-out expected in Q2 2023; a
first-in-class, intranasally administered RNA-based immunotherapy for
respiratory virus infections (POLB 002); and a vaccine candidate for
Melioidosis (POLB 003). The Company is also developing an Oral Vaccine
Platform and is progressing two Artificial Intelligence (AI) Programmes to
accelerate the power of its human challenge model data and biobank, with
results from the first programme expected by year end.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

Further detail on POLB 001

 

This trial is a randomised, double-blind, placebo-controlled, multiple dose,
LPS human challenge trial in 36 healthy volunteers to assess the potential
efficacy of POLB 001 in treating the hyperinflammatory responses associated
with severe influenza. As part of the trial, researchers stimulated the immune
systems of healthy volunteers with LPS across three cohorts. LPS triggers a
robust immune response and acts as a surrogate for the hyperinflammatory
effects associated with severe influenza infection, as well as other diseases.
Each cohort received escalating doses of POLB 001 to evaluate its
effectiveness in suppressing the body's harmful inflammatory response to both
intradermal (a shallow injection) and intravenous (an injection in a vein)
administered LPS, which will produce a broad-ranging dataset.

 

Given POLB 001's mode of action, it is viral strain agnostic as it treats the
body's reaction to infection rather than targeting the virus directly and, as
such, POLB 001 is unaffected by the seasonal variants of influenza that arise
each year which is a significant advantage over influenza treatments available
on the market. Therefore, POLB 001 has the potential to be a transformational
treatment for patients and to become a leading severe influenza treatment.
POLB 001 has patent protection until 2038 and is a shelf-stable oral drug
which makes it ideal as a stockpiling candidate for both seasonal outbreaks
and pandemic preparedness.

 

POLB 001 also has potential therapeutic applications beyond severe influenza,
due to its mode of action of reducing hyperinflammation (cytokine storm). This
is when harmful inflammation occurs in different areas of the body, such as
the heart and lungs, causing organ damage which is linked with many diseases.
POLB 001 has the potential to block this by interrupting the positive feedback
loop of inflammatory mediators. Poolbeg is currently investigating new
potential uses and in due course hopes to expand its IP around this asset to
cover new disease areas thereby increasing the value of the asset.

 

The data collected in the previous Phase I study demonstrated that POLB 001
administration produces a potent and long-lasting inhibition of p38 MAP Kinase
activity in humans. The study showed that after administration of single doses
up to 600 mg and repeated doses up to 150 mg there were neither serious nor
limiting adverse events to POLB 001, and that after a twice daily dose of
150mg an inhibition of LPS-induced TNFα of between 70% and 90% was
achieved.

 

About Influenza

 

Influenza is a viral pathogen that infects approximately one-eighth of the
world's population each year, an estimated 1 billion people infected globally,
attacking the respiratory system leading to between 5 and 10 million
hospitalisations and as many as 500,000 influenza related deaths. Survivors of
severe influenza can suffer organ damage, leading to chronic and life-changing
injuries. Complications include a 6-fold increased risk of heart attack, an
8-fold increased risk of Pneumonia, and an 8-fold increased risk of stroke.
This leads to an enormous compound cost of treatment - influenza contributes
to an estimated economic burden of $11.2bn every year in the US alone.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURFSSEFUEESESE